



**EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY
PRODUCTS AND PIPELINE AT 50TH ASCO ANNUAL MEETING**

***HIGHLIGHTS INCLUDE NEW PHASE III CLINICAL DATA ON INVESTIGATIONAL ANTICANCER
AGENT LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER***

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven[®] (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "eribulin") and lenvatinib (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode) will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 30 to June 3, 2014.

The main presentations for this year's ASCO meeting include oral presentations highlighting the results of a Phase III study (the SELECT (Study of E7080 LEnvatinib in differentiated Cancer of the Thyroid) study, Study 303) wi

Lenvatinib (E7080) Abstract No: TPS4153	A multicenter, open-label, phase III trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. Poster Presentation May 31 (Sat), 8:00-11:45
Lenvatinib (E7080) Abstract No: 8043	E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC). Poster Presentation June 1 (Sat), 13:15-17:00
Eribulin (Halaven®) Abstract No: 631	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status. Poster Presentation June 2 (Mon), 08:00-11:45
Eribulin (Halaven®) Abstract No: 629	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies. Poster Presentation June 2 (Mon), 08:00-11:45
Eribulin (Halaven®) Abstract No: 635	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study. Poster Presentation June 2 (Mon), 08:00-11:45
Eribulin (Halaven®) Abstract No: TPS670	Phase II feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC). Poster Presentation June 2 (Mon), 08:00-11:45
Eribulin (Halaven®) Abstract No: 10567	Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS). Poster Presentation June 2 (Mon), 08:00-11:45

Eribulin
(Halaven®)

Abstract No: 2595